Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.
- DOI
- 10.1007/s00259-020-04832-9
- Published
- 2020 Dec
- Container
- European journal of nuclear medicine and molecular imaging
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00259-020-04832-9,
title = {Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.},
author = {Krebs S and O'Donoghue JA and Biegel E and Beattie BJ and Reidy D and Lyashchenko SK and Lewis JS and Bodei L and Weber WA and Pandit-Taskar N},
year = {2020},
journal = {European journal of nuclear medicine and molecular imaging},
doi = {10.1007/s00259-020-04832-9},
url = {https://doi.org/10.1007/s00259-020-04832-9}
}RIS
TY - JOUR TI - Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. AU - Krebs S AU - O'Donoghue JA AU - Biegel E AU - Beattie BJ AU - Reidy D AU - Lyashchenko SK AU - Lewis JS AU - Bodei L AU - Weber WA AU - Pandit-Taskar N PY - 2020 JO - European journal of nuclear medicine and molecular imaging DO - 10.1007/s00259-020-04832-9 UR - https://doi.org/10.1007/s00259-020-04832-9 ER -
APA
S, K., JA, O., E, B., BJ, B., D, R., SK, L., JS, L., L, B., WA, W., & N, P. (2020). Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.. European journal of nuclear medicine and molecular imaging. https://doi.org/10.1007/s00259-020-04832-9
Source records
- pubmed · retrieved 2026-09-26T08:33:13.989Z
- europe-pmc · retrieved 2026-09-26T08:33:14.001Z